POTENTIAL CONFLICT OF INTEREST: Within the past 12 months, Dr Gibbons was a consultant for Sarepta Therapeutics and attended an advisory board meeting; the other authors have indicated they have no potential conflicts of interest to disclose. Significant progress has been made in managing the medical needs of patients who have Duchenne muscular dystrophy (DMD). As a result, many patients live well into adulthood and have the potential to lead independent, productive lives. However, the challenge of coping with a chronic and progressive illness from childhood into young adulthood is formidable. Close monitoring and appropriate interventions focused on improving emotional and social functioning should be The guidelines or recommendations in this article are not American Academy of Pediatrics policy, and publication herein does not imply endorsement. In this article, we outline a comprehensive plan for the psychosocial management of patients with Duchenne muscular dystrophy (DMD) across the life span. In 2010, the Centers for Disease Control and Prevention sponsored the development of multidisciplinary management guidance for DMD, and in 2018, that guidance was updated. In the intervening years, a new emphasis was placed on studying and addressing the psychosocial issues that affect patients with DMD, driven in part by improved patient survival. Once viewed as ancillary to managing the significant medical needs of patients with DMD, it is now standard practice to integrate psychosocial management into the multidisciplinary management of the disease. It is also increasingly recognized that neurodevelopmental disorders in DMD occur at a higher rate than what was previously understood and that these disorders warrant early and intensive intervention. In this article, we expand on the content found in the 2018 DMD Care Considerations.